{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:42:32Z","timestamp":1782387752296,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Leipzig"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Chimeric antigen receptor (CAR)-T cells are a viable treatment option for patients with relapsed or refractory (r\/r) aggressive B-cell lymphomas. The prognosis of patients who relapse after CAR-T cell treatment is dismal and factors predicting outcomes need to be identified. Our aim was to assess the value of FDG-PET\/CT in terms of predicting patient outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Twenty-two patients with r\/r B-cell lymphoma who received CAR-T cell treatment with tisagenlecleucel (<jats:italic>n<\/jats:italic>\u2009=\u200917) or axicabtagene ciloleucel (<jats:italic>n<\/jats:italic>\u2009=\u20095) underwent quantitative FDG-PET\/CT before (PET-0) and 1\u00a0month after infusion of CAR-T cells (PET-1). PET-1 was classified as complete metabolic response (CMR, Deauville score 1\u20133) or non-CMR (Deauville score 4\u20135).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At the time of PET-1, 12\/22 (55%) patients showed CMR, ten (45%) patients non-CMR. 7\/12 (58%) CMR patients relapsed after a median of 223\u00a0days, three of them (25%) died. 9\/10 (90%) non-CMR patients developed relapse or progressive disease after a median of 91\u00a0days, eight of them (80%) died. CMR patients demonstrated a significantly lower median total metabolic tumor volume (TMTV) in PET-0 (1\u00a0ml) than non-CMR patients (225\u00a0ml).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results confirm the prognostic value of PET-1. 42% of all CMR patients are still in remission 1\u00a0year after CAR T-cell treatment. 90% of the non-CMR patients relapsed, indicating the need for early intervention. Higher TMTV before CAR-T cell infusion was associated with lower chances of CMR.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-023-04587-4","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T05:32:10Z","timestamp":1674279130000},"page":"6131-6138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Prognostic value of baseline and early response FDG-PET\/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy"],"prefix":"10.1007","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6066-8753","authenticated-orcid":false,"given":"Thomas Walter","family":"Georgi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-4880","authenticated-orcid":false,"given":"Lars","family":"Kurch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8239-002X","authenticated-orcid":false,"given":"Georg-Nikolaus","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2270-0804","authenticated-orcid":false,"given":"Madlen","family":"Jentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1315-2332","authenticated-orcid":false,"given":"Sebastian","family":"Schwind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Perez-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naima","family":"Petermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2805-5973","authenticated-orcid":false,"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3920-7490","authenticated-orcid":false,"given":"Klaus","family":"Metzeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Borte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7473-7476","authenticated-orcid":false,"given":"Marco","family":"Herling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3313-3208","authenticated-orcid":false,"given":"Timm","family":"Denecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1245-1290","authenticated-orcid":false,"given":"Regine","family":"Kluge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6425-3504","authenticated-orcid":false,"given":"Osama","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8398-285X","authenticated-orcid":false,"given":"Vladan","family":"Vu\u010dini\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"4587_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"6736","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 6736:1\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0","journal-title":"Lancet"},{"key":"4587_CR2","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1182\/BLOODADVANCES.2021006715","volume":"6","author":"A Al Zaki","year":"2022","unstructured":"Al Zaki A, Feng L, Watson G et al (2022) Day 30 SUVmax predicts progression in patients with lymphoma achieving PR\/SD after CAR T-cell therapy. Blood Adv 6:2867\u20132871. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2021006715","journal-title":"Blood Adv"},{"key":"4587_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-022-01969-y","volume":"2022","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R et al (2022) A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med 2022:1\u201310. https:\/\/doi.org\/10.1038\/s41591-022-01969-y","journal-title":"Nat Med"},{"key":"4587_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","volume":"44","author":"SF Barrington","year":"2017","unstructured":"Barrington SF, Kluge R (2017) FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging 44:97\u2013110. https:\/\/doi.org\/10.1007\/s00259-017-3690-8","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4587_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1182\/blood.2021015209","volume":"140","author":"WA Bethge","year":"2022","unstructured":"Bethge WA, Martus P, Schmitt M et al (2022) GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood 140:349\u2013358. https:\/\/doi.org\/10.1182\/blood.2021015209","journal-title":"Blood"},{"key":"4587_CR6","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1182\/bloodadvances.2019000151","volume":"3","author":"MR Bishop","year":"2019","unstructured":"Bishop MR, Maziarz RT, Waller EK et al (2019) Tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. Blood Adv 3:2230\u20132236. https:\/\/doi.org\/10.1182\/bloodadvances.2019000151","journal-title":"Blood Adv"},{"key":"4587_CR7","doi-asserted-by":"publisher","first-page":"E152","DOI":"10.1097\/RLU.0000000000003870","volume":"47","author":"C Boursier","year":"2022","unstructured":"Boursier C, Perrin M, Bordonne M et al (2022) Early 18F-FDG PET flare-up phenomenon after CAR T-Cell therapy in lymphoma. Clin Nucl Med 47:E152\u2013E153. https:\/\/doi.org\/10.1097\/RLU.0000000000003870","journal-title":"Clin Nucl Med"},{"key":"4587_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-022-01256-w","volume":"15","author":"WG Breen","year":"2022","unstructured":"Breen WG, Hathcock MA, Young JR et al (2022) Metabolic characteristics and prognostic differentiation of aggressive lymphoma using 1-month post-CAR-T FDG PET\/CT. J Hematol Oncol 15:36. https:\/\/doi.org\/10.1186\/s13045-022-01256-w","journal-title":"J Hematol Oncol"},{"key":"4587_CR9","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification. J Clin Oncol 32:3059\u20133067","journal-title":"J Clin Oncol"},{"key":"4587_CR10","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/BLOOD-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L et al (2016) Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128:2489\u20132496. https:\/\/doi.org\/10.1182\/BLOOD-2016-05-718528","journal-title":"Blood"},{"key":"4587_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/S00259-021-05551-5","author":"D Cohen","year":"2021","unstructured":"Cohen D, Luttwak E, Beyar-Katz O et al (2021) [18 F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/S00259-021-05551-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4587_CR12","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/BLOODADVANCES.2020001900","volume":"4","author":"EA Dean","year":"2020","unstructured":"Dean EA, Mhaskar RS, Lu H et al (2020) High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4:3268\u20133276. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2020001900","journal-title":"Blood Adv"},{"key":"4587_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12149-020-01544-w","volume":"35","author":"T Derlin","year":"2021","unstructured":"Derlin T, Schultze-Florey C, Werner RA et al (2021) 18F-FDG PET\/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. Ann Nucl Med 35:132\u2013138. https:\/\/doi.org\/10.1007\/s12149-020-01544-w","journal-title":"Ann Nucl Med"},{"key":"4587_CR14","unstructured":"DRST Annual Report (2021). http:\/\/www.drst.de\/drst\/download\/jb2021.pdf. Assessed 15 Dec 2022"},{"key":"4587_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/jpm11030217","volume":"11","author":"C Ferrari","year":"2021","unstructured":"Ferrari C, Maggialetti N, Masi T et al (2021) Early evaluation of immunotherapy response in lymphoma patients by 18F-FDG PET\/CT: a literature overview. J Pers Med 11:217. https:\/\/doi.org\/10.3390\/jpm11030217","journal-title":"J Pers Med"},{"key":"4587_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496\u2013509. https:\/\/doi.org\/10.1080\/01621459.1999.10474144","journal-title":"J Am Stat Assoc"},{"key":"4587_CR17","doi-asserted-by":"publisher","DOI":"10.2967\/JNUMED.122.264112","author":"TW Georgi","year":"2022","unstructured":"Georgi TW, Stoevesandt D, Kurch L et al (2022) Optimized whole-body positron emission tomography magnetic resonance imaging sequence workflow in pediatric Hodgkin lymphoma patients. J Nucl Med. https:\/\/doi.org\/10.2967\/JNUMED.122.264112","journal-title":"J Nucl Med"},{"key":"4587_CR18","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/S00259-014-2715-9","volume":"41","author":"D Hasenclever","year":"2014","unstructured":"Hasenclever D, Kurch L, Mauz-K\u00f6rholz C et al (2014) qPET\u2014a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging 41:1301\u20131308. https:\/\/doi.org\/10.1007\/S00259-014-2715-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4587_CR19","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","volume":"133","author":"AV Hirayama","year":"2019","unstructured":"Hirayama AV, Gauthier J, Hay KA et al (2019) The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood 133:1876\u20131887. https:\/\/doi.org\/10.1182\/blood-2018-11-887067","journal-title":"Blood"},{"key":"4587_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2021.713577","author":"R Hong","year":"2021","unstructured":"Hong R, Tan SYE, Wang L et al (2021) Tumor burden measured by 18F-FDG PET\/CT in predicting efficacy and adverse effects of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphoma. Front Oncol. https:\/\/doi.org\/10.3389\/FONC.2021.713577","journal-title":"Front Oncol"},{"key":"4587_CR21","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1007\/s00277-021-04560-6","volume":"100","author":"G Iacoboni","year":"2021","unstructured":"Iacoboni G, Sim\u00f3 M, Villacampa G et al (2021) Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. Ann Hematol 100:2303\u20132310. https:\/\/doi.org\/10.1007\/s00277-021-04560-6","journal-title":"Ann Hematol"},{"key":"4587_CR22","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.2967\/JNUMED.120.255034","volume":"62","author":"L Kurch","year":"2021","unstructured":"Kurch L, H\u00fcttmann A, Georgi TW et al (2021) Interim PET in diffuse large B-Cell lymphoma. J Nucl Med 62:1068\u20131074. https:\/\/doi.org\/10.2967\/JNUMED.120.255034","journal-title":"J Nucl Med"},{"key":"4587_CR23","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2022.280805","author":"M Kwon","year":"2022","unstructured":"Kwon M, Iacoboni G, Reguera JL et al (2022) Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. https:\/\/doi.org\/10.3324\/HAEMATOL.2022.280805","journal-title":"Haematologica"},{"key":"4587_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20:31\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7","journal-title":"Lancet Oncol"},{"key":"4587_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","volume":"23","author":"C Mauz-K\u00f6rholz","year":"2022","unstructured":"Mauz-K\u00f6rholz C, Landman-Parker J, Balwierz W et al (2022) Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, mult. Lancet Oncol 23:125\u2013137. https:\/\/doi.org\/10.1016\/S1470-2045(21)00470-8","journal-title":"Lancet Oncol"},{"key":"4587_CR26","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/10428190903040048","volume":"50","author":"M Meignan","year":"2009","unstructured":"Meignan M, Gallamini A, Meignan M et al (2009) Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma 50:1257\u20131260. https:\/\/doi.org\/10.1080\/10428190903040048","journal-title":"Leuk Lymphoma"},{"key":"4587_CR27","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1080\/10428194.2017.1298752","volume":"58","author":"C Nanni","year":"2017","unstructured":"Nanni C, Cottereau AS, Lopci E et al (2017) Report of the 6th International Workshop on PET in lymphoma. Leuk Lymphoma 58:2298\u20132303. https:\/\/doi.org\/10.1080\/10428194.2017.1298752","journal-title":"Leuk Lymphoma"},{"key":"4587_CR28","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L et al (2020) Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol 38:3119\u20133128. https:\/\/doi.org\/10.1200\/JCO.19.02104","journal-title":"J Clin Oncol"},{"key":"4587_CR29","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/blood-2019-03-900928","volume":"133","author":"SS Neelapu","year":"2019","unstructured":"Neelapu SS (2019) CAR-T efficacy: is conditioning the key? Blood 133:1799\u20131800. https:\/\/doi.org\/10.1182\/blood-2019-03-900928","journal-title":"Blood"},{"key":"4587_CR30","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med 377:2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"4587_CR31","unstructured":"R Core Team R Core Team (2020) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria"},{"key":"4587_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/JCM11061522","author":"CP Reinert","year":"2022","unstructured":"Reinert CP, Perl RM, Faul C et al (2022) Value of CT-textural features and volume-based pet parameters in comparison to serologic markers for response prediction in patients with diffuse large B-cell lymphoma undergoing CD19-CAR-T cell therapy. J Clin Med. https:\/\/doi.org\/10.3390\/JCM11061522","journal-title":"J Clin Med"},{"key":"4587_CR33","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA et al (2017) Chimeric antigen receptor T Cells in refractory B-Cell lymphomas. N Engl J Med 377:2545\u20132554. https:\/\/doi.org\/10.1056\/NEJMoa1708566","journal-title":"N Engl J Med"},{"key":"4587_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med 380:45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"key":"4587_CR35","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/RLU.0000000000003756","volume":"46","author":"P Sesques","year":"2021","unstructured":"Sesques P, Tordo J, Ferrant E et al (2021) Prognostic Impact of 18F-FDG PET\/CT in patients with aggressive B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T cells. Clin Nucl Med 46:627\u2013634. https:\/\/doi.org\/10.1097\/RLU.0000000000003756","journal-title":"Clin Nucl Med"},{"key":"4587_CR36","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/J.JCYT.2018.10.003","volume":"20","author":"NN Shah","year":"2018","unstructured":"Shah NN, Nagle SJ, Torigian DA et al (2018) Early positron emission tomography\/computed tomography as a predictor of response after CTL019 chimeric antigen receptor-T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy 20:1415\u20131418. https:\/\/doi.org\/10.1016\/J.JCYT.2018.10.003","journal-title":"Cytotherapy"},{"key":"4587_CR37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006245","author":"JY Spiegel","year":"2020","unstructured":"Spiegel JY, Dahiya S, Jain MD et al (2020) Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel. Blood. https:\/\/doi.org\/10.1182\/blood.2020006245","journal-title":"Blood"},{"key":"4587_CR38","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Di Blasi R, Kanoun S et al (2020) Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv 4:5607\u20135615. https:\/\/doi.org\/10.1182\/bloodadvances.2020003001","journal-title":"Blood Adv"},{"key":"4587_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2021.664688","author":"L Vercellino","year":"2021","unstructured":"Vercellino L, de Jong D, di Blasi R et al (2021) Current and future role of medical imaging in guiding the management of patients with relapsed and refractory non-Hodgkin lymphoma treated with CAR T-cell therapy. Front Oncol. https:\/\/doi.org\/10.3389\/FONC.2021.664688","journal-title":"Front Oncol"},{"key":"4587_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2021.713401","volume":"8","author":"V Vucinic","year":"2021","unstructured":"Vucinic V, Quaiser A, L\u00fcckemeier P et al (2021) Production and application of CAR T cells: current and future role of Europe. Front Med 8:1\u20139. https:\/\/doi.org\/10.3389\/fmed.2021.713401","journal-title":"Front Med"},{"key":"4587_CR41","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/J.BBMT.2019.02.008","volume":"25","author":"J Wang","year":"2019","unstructured":"Wang J, Hu Y, Yang S et al (2019) Role of fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma. Biol Blood Marrow Transplant 25:1092\u20131098. https:\/\/doi.org\/10.1016\/J.BBMT.2019.02.008","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04587-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04587-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04587-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T12:15:01Z","timestamp":1689768901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04587-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4587"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04587-4","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"assertion":[{"value":"18 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VV, GNF, MH, UP: honoraria from Novartis and Gilead\/Kite. Other coauthors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}